This meta-analysis showed that when initiated at the prediabetic stage, interventions with medications, specifically SGLT-2 inhibitors and GLP-1 receptor agonists, show promising evidence in delaying the progression of prediabetes into diabetes. The gene discussed is SLC5A2; the disease is prediabetes syndrome.